Cue Biopharma (NASDAQ:CUE) CEO Shao-Lee Lin Sells 18,258 Shares of Stock

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Shao-Lee Lin sold 18,258 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $28.62, for a total transaction of $522,543.96. Following the sale, the chief executive officer owned 705,995 shares of the company’s stock, valued at approximately $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shao-Lee Lin also recently made the following trade(s):

• On Wednesday, August 12th, Shao-Lee Lin sold 40,000 shares of Cue Biopharma stock. The stock was sold at an average price of $27.10, for a total transaction of $1,084,000.00.

Cue Biopharma Stock Performance

Shares of NASDAQ:CUE traded up $3.12 during trading on Friday, reaching $34.20. 157,074 shares of the stock traded hands, compared to its average volume of 195,652. The stock has a 50-day moving average of $29.50 and a two-hundred day moving average of $147.28. Cue Biopharma, Inc. has a 52-week low of $4.97 and a 52-week high of $45.50. The stock has a market cap of $143.64 million, a P/E ratio of -6.12 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.69) by ($22.45). The firm had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 98.30% and a negative net margin of 59.65%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CUE. ADAR1 Capital Management LLC purchased a new position in Cue Biopharma in the second quarter worth about $1,742,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $83,000. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $722,000. BlackRock Inc. purchased a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $1,824,000. Finally, Persistent Asset Partners Ltd bought a new position in shares of Cue Biopharma in the 2nd quarter worth approximately $389,000. Institutional investors own 35.04% of the company’s stock.

Analysts Set New Price Targets

CUE has been the subject of several recent analyst reports. Wall Street Zen upgraded Cue Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Weiss Ratings upgraded Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.